VCaP Cells
545,10 CAD$*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
Renseignements généraux
| Description | The VCaP (Vertebral-Cancer of the Prostate) cell line is an important model in the study of prostate cancer, derived from a vertebral metastasis of a human prostate carcinoma. It was established to provide a relevant in vitro model for researching the biology of prostate cancer and its metastatic process, particularly focusing on hormone-refractory stages of the disease. VCaP cells are known for expressing a high level of prostate-specific antigen (PSA) and androgen receptor (AR), making them highly relevant for studies on androgen receptor signaling pathways and resistance mechanisms to anti-androgen therapy. VCaP cells are also utilized extensively in genetic studies, as they harbor the TMPRSS2-ERG gene fusion, a common chromosomal translocation found in approximately 50% of prostate cancer cases. This specific genetic alteration is significant because it is thought to play a crucial role in the progression of prostate cancer. The cells are thus an excellent tool for research aiming to understand the molecular underpinnings of prostate cancer and for the development of new therapeutic strategies targeting TMPRSS2-ERG and related pathways. Moreover, VCaP cells exhibit robust in vitro growth and can form tumors when xenografted in immunodeficient mice, providing a useful system for preclinical studies of new anticancer drugs. Overall, the VCaP cell line serves as a vital resource for molecular and pharmacological studies, contributing significantly to the understanding of prostate cancer biology and the assessment of new therapeutic agents. Its characteristics, including hormone responsiveness, gene fusion expression, and metastatic origin, make it uniquely suitable for advanced prostate cancer research, particularly in areas related to androgen independence and metastatic disease progression. |
|---|---|
| Organisme | Human |
| Tissu | Prostate |
| Maladie | Prostate carcinoma |
| Site métastatique | Bone, vertebra |
| Synonymes | VCAP, Vcap, Vertebral Cancer of the Prostate |
Caractéristiques
| Âge | 59 years |
|---|---|
| Genre | Male |
| Origine ethnique | European |
| Propriétés de croissance | Adherent |
Données réglementaires
| Référence | VCaP (Cytion catalog number 300631) |
|---|---|
| Niveau de biosécurité | VCaP cells are classified as Biosafety Level 1 (BSL-1) for standard lab work. However, for genetic engineering, the ZKBS classifies them as Biosafety Level 2 (BSL-2). |
| NCBI_Numéro d'identification fiscale | 9606 |
| Cellosaurus - Numéro d'enregistrement | CVCL_2235 |
Données biomoléculaires
| Expression de l'antigène | P53 antigen, Cytokeratin-18, prostate-specific antigen, prostatic acid phosphatase, Rb protein |
|---|---|
| Tumorigène | Yes, in SCID mice |
| Virus | Mouse xenotropic retrovirus Bxv-1 |
Manipulation
| Milieu de culture | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Suppléments | Supplement the medium with 10% FBS |
| Réactif de dissociation | Accutase |
| Temps de doublement | Slow growing cell line, doubling time 5-6 days. |
| Repiquage | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Densité de semis | 4-8 x 104 cells/cm2 |
| Milieu de congélation | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Décongélation et culture des cellules |
|
| Atmosphère d'incubation | 37°C, 5% CO2, humidified atmosphere. |
| Conditions d'expédition | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Conditions d'entreposage | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Contrôle de la qualité et analyse moléculaire
| Stérilité | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificat d'analyse (CoA)
| Numéro de lot | Type de certificat | Date | Numéro de catalogue |
|---|---|---|---|
| 300631-181223 | Certificat d'analyse | 23. May. 2025 | 300631 |
| 300631-201025 | Certificat d'analyse | 05. Dec. 2025 | 300631 |